SMi's inaugural Oligonucleotide Therapeutics and Delivery conference is here to keep you updated. By bringing together leading representatives of pharmaceutical, biotechnology and academic institutions, the 2-day conference will provide first-hand information on the latest clinical trial candidates and a pl...
SMi’s inaugural Oligonucleotide Therapeutics and Delivery conference is here to keep you updated. By bringing together leading representatives of pharmaceutical, biotechnology and academic institutions, the 2-day conference will provide first-hand information on the latest clinical trial candidates and a p...
drug delivery systemoligonucleotide therapeuticsConsiderable advances have been made in the research and development of oligonucleotide therapeutics (OTs) for treating central nervous system (CNS) diseases, such as psychiatric and neurodegenerative disorders, because of their promising mode of action. However...
Oligonucleotide Therapeutics 作者: Tuschl, Thomas (EDT)/ Rossi, John (EDT) 出版社: Blackwell Pub副标题: First Annual Meetingof The Oligonucleotide Therapeutics Society出版年: 2006-12页数: 300定价: $ 139.95装帧: PapISBN: 9781573315876豆瓣评分 目前无人评价 ...
(1888PressRelease)June 17, 2021- From optimizing particle size to choosing the right nanocarrier systems, Oligonucleotide Therapeutics and Delivery conference will address delivery to non-hepatocyte cells such as cancerous tissues and overview the most successful platforms. ...
Elsie is a private biopharmaceutical company dedicated to unlocking the full potential of oligonucleotide therapeutics by integrating discovery, development, and delivery to potentially increase potency, decrease toxicity, and optimise delivery. About GSK ...
Unrivaled Speed:Production to delivery with 4-6 weeks Scale For Growth:25 mgs to kilograms of oligos, delivered on-spec and on-time Customized Quality Offerings:RUO, GMP-like, and GMP production is available Experienced Scientists:18 years experience in custom oligo synthesis...
F. GalNAc–siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid. Ther. 28, 109–118 (2018). PubMed PubMed Central CAS Google Scholar Garber, K. Alnylam terminates revusiran program, stock plunges. Nat. Biotechnol. 34, 1213–1214 (2016). PubMed CAS Google ...
The industry's most renowned event to accelerate oligo, peptide, and mRNA/vaccine therapeutics to market: Leading strategies for expediting R&D & improving CMC efficiency.
Antisense oligonucleotide therapeutics: Drug delivery and targeting. Adv. Drug Delivery Rev. 18: 115-131, 1996. Stull et al. Antigene, ribozyme, and aptamer nucleic acid drugs; Progress and prospects. Pharm. Res. 12(4): 465-483, Apr. 1995. Yarchoan et al. Development of antiretroviral...